Treatment Survival and Reasons for Discontinuation in Patients with Recalcitrant Folliculitis Decalvans

The study on recalcitrant folliculitis decalvans (FD) in 18 patients over a median follow-up of 1.5 years revealed high discontinuation rates for systemic antibiotics, such as tetracyclines and a combination of rifampicin and clindamycin, used by 88.9% of participants. Non-biological systemic therapies, particularly isotretinoin, were used by 61.1% of patients. The findings emphasize the necessity for effective immunomodulatory treatments and suggest that a personalized, multifaceted approach, combining local and systemic therapies, is crucial for managing severe FD.